Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
Key Highlights
- ➤Rosemont to acquire Aytu (AYTU) for $2.70 per share in cash
- ➤Tender offer requires at least majority of Aytu shares and warrant resolution
- ➤Rosemont intends to commence tender offer within 10 business days
- ➤Aytu board unanimously approved transaction; closing expected in late December 2026
Expert Statements
Josh Disbrow, Chief Executive Officer of Aytu BioPharma
“This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve. We see a strong strategic fit between our portfolio and Rosemont's experience developing and commercializing specialty medicines. Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”
Alok Sonig, Chief Executive Officer of Rosemont Pharmaceuticals
“The proposed acquisition of Aytu marks an important step in Rosemont's US growth strategy. Aytu has built an established CNS adult and pediatric-focused specialty pharmaceutical business with talented people, a differentiated portfolio and proven commercial capabilities. Together with Rosemont's product development, regulatory, manufacturing and commercial expertise, we believe we can build a strong platform for future growth. We look forward to welcoming the Aytu team once the transaction is complete.”
DENVER, CO / ACCESS Newswire / November 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it has entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc. ("Rosemont"), pursuant to which Rosemont would acquire Aytu, through a tender offer for $2.70 per share.
Under the terms of the merger agreement, a wholly-owned subsidiary of Rosemont will commence a tender offer to acquire all outstanding shares of Aytu common stock. The transaction is structured as a tender offer to be followed by a merger, subject to customary conditions to the tender offer and merger, including the tender of shares representing at least a majority of the total number of outstanding shares of Aytu common stock and the exercise or termination of certain outstanding warrants. Following the successful completion of the tender offer, Rosemont will acquire all remaining shares not tendered in the tender offer (other than shares for which appraisal rights are properly exercised) through a second-step merger at the same price paid in the tender offer.
Get started
Create a free account to read the full story.
